GLP-1 drugs continue to dominate the pharmaceutical landscape. The medication is popular for its weight loss applications, and major pharmaceutical companies continue to introduce new versions of ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
Financially, the agreement includes a $20 million upfront payment to C4 Therapeutics, with the potential for additional ...
The U.S. government awarded Shionogi Inc. a contract worth up to $482 million to expand domestic manufacturing of Fetroja ...
Pharmaceutical Executive: How does the complexity of obesity impact the effectiveness of GLP-1s? Mark Bagnall: This is one of ...
VESALIUS-CV data supported evolocumab reducing MACE in high-risk primary prevention diabetes over 4.8 years, reinforcing the ...
In today's Pharmaceutical Executive Daily, activist investor Shah Capital escalates its campaign against Novavax's board ...
Air route diversions and constrained regional access are eroding schedule certainty for temperature-controlled air freight, ...
In these gray areas, an advisory committee can be essential; it allows for a real-time debate on the benefit-risk profile ...
U.S. District Judge David Joseph, a Trump appointee sitting in Lafayette, Louisiana, refused Louisiana Attorney General Liz ...
Shah Capital plans “against” votes on directors and say-on-pay, while seeking to sway ISS and Glass Lewis rather than running ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results